A new study published on 29 June 2025 in international peer-reviewed medical journal Expert Opinion on Drug Safety by Frey et al. has found that use of depot medroxyprogesterone acetate, which is manufactured by Pfizer (PFE) and sold under the brand name Depo-Provera among others, for over one year is associated with a 3.5-fold increased risk of developing an intracranial meningioma, a type of brain tumour, compared to the use of the combined birth control pill Ethinylestradiol/levonorgestrel. The study used a database of 114 million unique individuals in its research. A Multi-District Litigation is being brought on behalf of women in the USA who developed meningiomas after receiving at least 4 consecutive injections of Pfizer’s Depo-Provera.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PFE:
- Pfizer completes licensing agreement with 3SBio
- Hold Rating on Pfizer Due to Tafamidis Patent Expiration Risks and Revenue Decline Concerns
- Pfizer’s INLYTA® Study in Taiwan: Key Insights for Investors
- Pfizer’s BeneFIX Study Update: Key Insights for Investors
- Pfizer’s Hemophilia Study: Insights into Treatment Patterns and Outcomes